Innovative Drug DeliveryMAT2203 is an application of Matinas's lipid nanocrystal (LNC) delivery that makes amphotericin available by oral administration and has demonstrated safety at high doses for sustained periods of time.

Partnership AgreementMatinas announced it entered a non-binding agreement with an undisclosed partner for global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections.

Bears Say

Financial HealthThe company lacks funds to materially advance any programs forward.

Leadership ChangesMatinas is implementing 80% workforce reduction, eliminating 15 positions, including departure of the CMO, CBO and CTO.

Strategic PartnershipPartnering negotiations for its lead asset MAT2203 were terminated by the prospective partner.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

16.51%

Insiders

1.96% Mutual Funds

1.24% Other Institutional Investors

79.14% Public Companies and Individual Investors

Detailed Ownership Overview >

MTNB FAQ

What was Matinas BioPharma’s price range in the past 12 months?

Matinas BioPharma lowest stock price was $0.47 and its highest was $9.63 in the past 12 months.

What is Matinas BioPharma’s market cap?

Matinas BioPharma’s market cap is $5.04M.

When is Matinas BioPharma’s upcoming earnings report date?

Matinas BioPharma’s upcoming earnings report date is Aug 19, 2025 which is in 37 days.

How were Matinas BioPharma’s earnings last quarter?

Matinas BioPharma released its earnings results on May 08, 2025. The company reported -$0.326 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.326.

Is Matinas BioPharma overvalued?

According to Wall Street analysts Matinas BioPharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Matinas BioPharma pay dividends?

Matinas BioPharma does not currently pay dividends.

What is Matinas BioPharma’s EPS estimate?

Matinas BioPharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Matinas BioPharma have?

Matinas BioPharma has 5,086,985 shares outstanding.

What happened to Matinas BioPharma’s price movement after its last earnings report?

Matinas BioPharma reported an EPS of -$0.326 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.408%.

Which hedge fund is a major shareholder of Matinas BioPharma?

Currently, no hedge funds are holding shares in MTNB

Company Description

Matinas BioPharma

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.